Numerous must mean at least five. If OM results are stellar, as we all expect, Uncle Leo will have ZERO excuses for not returning a mega deal for Brilacidin. With "numerous" pharmaceuticals interested in Brilacidin, good results (which is what we've seen thus far) should result in competition for the right to Brilacidin. If Leo can't ink a major deal for B during q1 2018 it will mean we shareholders have overestimated the results to date.
This PR has given Leo no room to hide pending good OM results. In that sense, I actually love this PR. Leo is now accountable to True Longs.